U.S. patent application number 14/476953 was filed with the patent office on 2015-01-15 for ventilatory assistance for treatment of cardiac failure and cheyne-stokes breathing.
The applicant listed for this patent is ResMed Limited. Invention is credited to Michael Berthon-Jones.
Application Number | 20150013679 14/476953 |
Document ID | / |
Family ID | 3807913 |
Filed Date | 2015-01-15 |
United States Patent
Application |
20150013679 |
Kind Code |
A1 |
Berthon-Jones; Michael |
January 15, 2015 |
VENTILATORY ASSISTANCE FOR TREATMENT OF CARDIAC FAILURE AND
CHEYNE-STOKES BREATHING
Abstract
Method and apparatus for the treatment of cardiac failure,
Cheyne Stokes breathing or central sleep apnea are disclosed. A
subject is provided with ventilatory support. Respiratory airflow
is determined. From the respiratory airflow are derived a measure
of instantaneous ventilation (for example half the absolute value
of the respiratory airflow) and a measure of longterm average
ventilation. A target ventilation is taken as 95% of the longterm
average ventilation. The instantaneous ventilation is fed as the
input signal to a clipped integral controller, with the target
ventilation as the reference signal. The output of the controller
determines the degree of ventilatory support. A third measure of
ventilation, for example instantaneous ventilation low pass
filtered with a time constant of 5 seconds, is calculated.
Ventilatory support is in phase with the subject's respiratory
airflow to the fuzzy extent that this ventilation is above target,
and at a preset rate conversely.
Inventors: |
Berthon-Jones; Michael;
(Leonay, AU) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
ResMed Limited |
Bella Vista |
|
AU |
|
|
Family ID: |
3807913 |
Appl. No.: |
14/476953 |
Filed: |
September 4, 2014 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
13962493 |
Aug 8, 2013 |
8857430 |
|
|
14476953 |
|
|
|
|
13114884 |
May 24, 2011 |
8528556 |
|
|
13962493 |
|
|
|
|
11457564 |
Jul 14, 2006 |
7967012 |
|
|
13114884 |
|
|
|
|
10865944 |
Jun 11, 2004 |
7077132 |
|
|
11457564 |
|
|
|
|
10374487 |
Feb 26, 2003 |
6951217 |
|
|
10865944 |
|
|
|
|
09316432 |
May 21, 1999 |
6532959 |
|
|
10374487 |
|
|
|
|
Current U.S.
Class: |
128/204.23 |
Current CPC
Class: |
A61M 16/0069 20140204;
A61M 16/024 20170801; A61M 16/00 20130101; A61M 2205/3303 20130101;
A61M 16/0057 20130101; A61M 16/0858 20140204; A61M 16/0051
20130101; A61M 2016/0039 20130101; A61M 16/0003 20140204; A61M
2230/42 20130101 |
Class at
Publication: |
128/204.23 |
International
Class: |
A61M 16/00 20060101
A61M016/00 |
Foreign Application Data
Date |
Code |
Application Number |
May 22, 1998 |
AU |
PP3663 |
Claims
1. A method for treatment of cardiac failure, Cheyne-Stokes
breathing or central sleep apnea, comprising the steps of:
providing a subject with ventilatory support; deriving a measure of
the subject's instantaneous ventilation; and adjusting the degree
of ventilatory support to reduce changes in said measure of
instantaneous ventilation over a timescale similar to that of the
waxing-waning cycle of untreated Cheyne-Stokes breathing or central
sleep apnea, while allowing changes in said measure of
instantaneous ventilation over a timescale much longer than said
waxing-waning cycle.
2. A method for treatment of cardiac failure, Cheyne-Stokes
breathing or central sleep apnea, comprising the steps of:
providing a subject with ventilatory support; deriving a measure of
the subject's instantaneous ventilation; deriving a measure of the
subject's longterm average ventilation; setting the controlled
variable of a servo-controller to a function of said measure of the
subject's instantaneous ventilation; setting the reference variable
of said servo-controller to a measure of the subject's longterm
average ventilation; and adjusting the magnitude of said
ventilatory support in accordance with the output of said
servo-controller.
3. A method for treatment of cardiac failure, Cheyne-Stokes
breathing or central sleep apnea, comprising the steps of:
providing a subject with ventilatory support; deriving a measure of
the subject's instantaneous ventilation; high pass filtering said
measure of the subject's instantaneous ventilation; and adjusting
the degree of said ventilatory support inversely with said high
pass filtered measure of the subject's instantaneous
ventilation.
4. A method as claimed in claim 1, whereby the step of adjusting
the degree of ventilator support comprises the steps of: low pass
filtering said measure of instantaneous ventilation to derive a
measure of longterm average ventilation; setting a target signal
equal to a fraction of said measure of longterm-average
ventilation; and servo-controlling said measure of instantaneous
ventilation to at least equal the target ventilation.
5. A method as claimed in claim 1, whereby ventilatory support is
positive pressure ventilatory support.
6. A method as claimed in claim 5, whereby the degree of
ventilatory support is the difference between a peak inspiratory
pressure and an end expiratory pressure.
7. A method as claimed in claim 1, whereby deriving a measure of
instantaneous ventilation comprises at least the steps of: deriving
a signal proportional to the subject's respiratory airflow; and
rectifying said signal.
8. A method as claimed in claim 1, whereby the degree of
ventilatory support provided is clipped to exceed a minimum degree
of support, chosen to be less than the degree of support that would
perform the subject's entire work of breathing.
9. A method as claimed in claim 1, whereby the degree of
ventilatory support provided is clipped to not exceed a maximum
degree of support, chosen to be sufficient to perform most or all
of the subject's work of breathing, but not sufficient to be
dangerous.
10. A method as claimed in claim 1, including the further steps of:
the severity of reduction in ventilation is determined; if the
severity of reduction in ventilation is high, then said ventilatory
support is provided at a preset rate; if the severity of reduction
in ventilation is zero, then said ventilatory support is provided
in phase with the subject's respiratory airflow; and for
intermediate degrees of severity of reduction in ventilation,
support is provided at an intermediate rate.
11. A method as claimed in claim 10, whereby the severity of
reduction in ventilation is calculated by comparing the subject's
ventilation with a low pass filtered ventilation.
12. Apparatus for the treatment of cardiac failure, Cheyne-Stokes
breathing or central sleep apnea, comprising: a device for
providing ventilatory support of controllable magnitude; means for
deriving a signal indicative of instantaneous ventilation of a
subject; and a servo-controller operable to control the degree of
ventilatory support provided by said ventilatory support device to
oppose short-term changes in said measure of instantaneous
ventilation, but permit longterm changes in said measure of
instantaneous ventilation.
13. Apparatus as claimed in claim 12, wherein the ventilatory
support device provides positive pressure ventilatory support.
14. Apparatus for treatment of cardiac failure, Cheyne-Stokes
breathing or central sleep apnea, comprising: a controllable source
of breathable gas at positive pressure; means for delivering said
breathable gas at positive pressure to a subject's airway; means
for deriving a measure of the subject's instantaneous ventilation;
and a servo-controller for adjusting the degree of ventilatory
support to reduce changes in said measure of instantaneous
ventilation over a timescale similar to that of the waxing-waning
cycle of untreated Cheyne-Stokes breathing or central sleep apnea,
while allowing changes in said measure of instantaneous ventilation
over a timescale much longer than said waxing-waning cycle.
15. Apparatus for treatment of cardiac failure, Cheyne-Stokes
breathing or central sleep apnea, comprising: a controllable source
of breathable gas at positive pressure; means for delivering said
breathable gas at positive pressure to a subject's airway; means
for deriving a measure of the subject's instantaneous ventilation;
means for deriving a measure of the subject's longterm average
ventilation; means for deriving a target ventilation as a function
of said measure of the subject's longterm average ventilation; a
servo-controller, whose input variable is a function of said
measure of the subject's instantaneous ventilation, and whose
reference variable is said target ventilation; and means for
adjusting the magnitude of said ventilatory support according to
the output of the servo controller.
16. Apparatus as claimed in claim 12 or claim 15, wherein said
measure of instantaneous ventilation is proportional to the
absolute value of the respiratory airflow.
17. Apparatus as claimed in claim 15, wherein said measure of the
subject's recent average ventilation is proportional to the low
pass filtered absolute value of the respiratory airflow, said low
pass filter having a time constant of the order of, or longer than
the waxing-waning cycle of untreated Cheyne-Stokes breathing.
18. Apparatus for treatment of cardiac failure, Cheyne-Stokes
breathing or central sleep apnea, comprising: a controllable source
of breathable gas at positive pressure; means for delivering said
breathable gas at positive pressure to a subject's airway; means
for deriving a measure of the subject's instantaneous ventilation;
means for high pass filtering said measure of the subject's
instantaneous ventilation; and a servo-controller whose input
variable is a function of said high pass filtered measure of the
subject's instantaneous ventilation, and which adjusts the
magnitude of said ventilatory support inversely with said high pass
filtered measure of the subject's instantaneous ventilation.
19. Apparatus as claimed in claim 18, wherein said high pass filter
has a time constant of the order of or longer than the
waxing-waning cycle of untreated Cheyne-Stokes breathing.
20. Apparatus as claimed in either one of claim 17 or claim 19,
wherein said time constant is 100 seconds.
21. Apparatus as claimed in claim 15, wherein said target
ventilation is a chosen fraction of the subject's recent average
ventilation.
22. Apparatus as claimed in claim 15, wherein the servo-control
means is operable to servo-control said measure of instantaneous
ventilation to at least equal the target ventilation.
23. Apparatus as claimed in either one of claim 15 or claim 22,
wherein the servo-control means is operable to increase the degree
of support if said measure of instantaneous ventilation is less
than said target ventilation, and reduce the degree of support if
said measure of instantaneous ventilation is greater than said
target ventilation.
24. Apparatus as claimed in claim 12, wherein the servo-control
means is further operable to clip the degree of ventilatory support
to exceed a minimum degree of support, chosen to be less than the
degree of support that would perform a subject's entire work of
breathing.
25. Apparatus as claimed in claim 12, wherein the servo-control
means is operable to modulate said positive said pressure in phase
with respiratory air flow where the subject is breathing
adequately, and to modulate said positive pressure at a preset rate
where the subject is not breathing adequately.
26. Apparatus as claimed in claim 25, wherein the servo-control
means is operable to assess the adequacy of breathing by comparing
a measure of instantaneous ventilation with a target
ventilation.
27. A method for the treatment of cardiac failure, Cheyne-Stokes
breathing or central sleep apnea, comprising the steps of:
providing a subject with positive pressure ventilatory support,
with controllable amplitude and rate; deriving a measure of the
subject's instantaneous ventilation; adjusting said amplitude of
positive pressure by: (a) low pass filtering said measure of
instantaneous ventilation to derive a measure of recent average
ventilation; (b) setting a target ventilation equal to a fraction
of said measure of recent average ventilation; and (c)
servo-controlling said measure of instantaneous ventilation to at
least equal the target ventilation, by adjusting the degree of
ventilator support; and continuously adjusting said rate by: (a) to
the extent that the instantaneous ventilation equals or exceeds
said target ventilation, modulating said positive pressure in phase
with respiratory airflow; and (b) to the extent that the
instantaneous ventilation is less than said target ventilation,
modulating said positive pressure at a preset rate.
28. Apparatus for the treatment of cardiac failure, Cheyne-Stokes
breathing or central sleep apnea, comprising: ventilator means for
providing ventilatory support with controllable amplitude and rate;
sensor and processing means for deriving a signal indicative of
instantaneous ventilation of a subject; and servo-control means
operable to adjust the amplitude of the pressure support by low
pass filtering said instantaneous ventilation signal to derive a
measure of recent average ventilation, setting a target ventilation
equal to a fraction of said measure of recent average ventilation
and servo-controlling said measure of instantaneous ventilation to
at least equal the target ventilation, and further operable to
continuously adjust said rate by modulating said positive pressure
in phase with respiratory airflow to the extent that the
instantaneous ventilation equals or exceeds said target
ventilation, and modulating said positive pressure at a pre-set
rate to the extent that the instantaneous ventilation is less than
said target ventilation.
29. A method for treatment of cardiac failure, Cheyne Stokes
breathing or central sleep apnea, comprising the steps of:
providing a subject with ventilatory support; deriving a measure of
instantaneous ventilation; and adjusting the degree of ventilatory
support to oppose short term changes in said measure of
instantaneous ventilation, but permitting longterm changes in said
measure of instantaneous ventilation.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] The present application is a continuation of U.S. patent
application Ser. No. 13/962,493, filed Aug. 8, 2013 which is a
continuation of U.S. patent application Ser. No. 13/114,884, filed
May 24, 2011, now U.S. Pat. No. 8,528,556 which is a continuation
of U.S. patent application Ser. No. 11/457,564 filed Jul. 14, 2006,
now U.S. Pat. No. 7,967,012, which is a continuation of U.S. patent
application Ser. No. 10/865,944 filed Jun. 11, 2004, now U.S. Pat.
No. 7,077,132, which is a continuation of U.S. patent application
Ser. No. 10/374,487 filed Feb. 26, 2003, now U.S. Pat. No.
6,951,217, which is a continuation of U.S. patent application Ser.
No. 09/316,432 filed May 21, 1999, now U.S. Pat. No. 6,532,959,
which claims priority from Australia PP3663 filed May 22, 1998, the
disclosure of which is hereby incorporated herein by reference.
FIELD OF THE INVENTION
[0002] The invention relates to methods and apparatus for the
provision of positive pressure ventilatory assistance for patients
with cardiac failure or Cheyne-Stokes breathing from any cause,
including central sleep apnea, cardiac failure or stroke.
EXPLANATION OF TERMS
[0003] In this specification, respiratory airflow is intended to
refer to the instantaneous flow of gas into or out of the lungs.
The term "average" is intended to mean any measure of central
tendency or the result of any low pass filtering operation.
Ventilatory support is intended to mean any procedure which has a
similar effect as the respiratory muscles, particularly the supply
of breathable gas under varying positive pressure to the airway via
a nosemask, face mask, endotracheal tube, tracheotomy tube, or the
like, but also including other procedures such as negative pressure
ventilation, cuirasse, iron lung, external chest compression, or
rocking bed ventilation. According to common usage, ventilation can
mean either a procedure, as in the expression "positive pressure
ventilation", or a measure of average respiratory airflow over a
period of time. Instantaneous ventilation is intended to mean the
volume inspired over a short period of time less than several
seconds. Equally it can be calculated as the volume expired over
such a period, or it can be the average of the two. For example,
measures of instantaneous ventilation would include half the
average of the absolute value of the respiratory airflow,
calculated over a time interval short compared with several
seconds, or half the absolute value of the respiratory airflow, low
pass filtered with a time constant short compared with several
seconds. For technical reasons to be explained below, in the best
embodiment, instantaneous ventilation is taken as half the absolute
value of the instantaneous respiratory airflow, ie averaged over an
arbitrarily short period of time. However, it is not intended that
the invention is limited to calculating instantaneous ventilation
in this way.
[0004] The term "varying A inversely with B" is intended in the
broad sense of increasing A if B is decreasing, and decreasing A if
B is increasing.
[0005] The term "servo-controller" here refers to a feedback
controller accepting an input, or controlled, variable (for example
actual measured ventilation) and a reference quantity (for example
a desired or target ventilation), and producing an output (for
example the settings of a ventilator) which is used to subsequently
bring the value of the input (controlled) variable towards the
value of the reference variable.
[0006] The term "oppose" can include reduce, limit, dampen, or
prevent.
[0007] The terms "recent average ventilation" and "longterm average
ventilation" are to be understood to be equivalents.
BACKGROUND OF THE INVENTION
[0008] Patients with cardiac failure have reduced cardiac ejection
fraction, are typically very breathless, and often wake at night
with extreme breathlessness called paroxysmal nocturnal dyspnea,
due to accumulation of fluid in the lungs.
[0009] Patients with cardiac failure also often have Cheyne-Stokes
breathing, particularly during sleep. Cheyne-Stokes breathing is an
abnormal limit cycle instability of the patient's respiratory
controller in which there are rhythmic alternating periods of
waxing and waning ventilation, causing repetitive deoxygenation and
reoxygenation of the arterial blood. The cause of the waxing and
waning of ventilation is not entirely clear, but there is an
increase in chemoreceptor gain [Wilcox I et al. Ventilatory control
in patients with sleep apnoea and left ventricular dysfunction:
comparison of obstructive and central sleep apnoea. 1998; 11:7-13],
possibly related to stimuli arising in the heart or lungs, a change
in the chemoreceptor set point leading to overventilation and
alkalosis in the awake state with apneas during sleep, and an
increase in circulation time leading to delays between ventilation
and chemoreception [Naughton M et al. Role of hyperventilation in
the pathogenesis of central sleep apneas in patients with
congestive heart failure. Am Rev Respir Dis 1993; 148:330-338].
Cheyne-Stokes breathing is associated with high mortality [Andreas
et al. Cheyne-Stokes respiration and prognosis in congestive heart
failure. Am J Cardiol 1996; 78:1260-1264]. It is possible that it
is harmful because of the repetitive hypoxia, which will lead to
hypoxic pulmonary vasoconstriction and high right heart afterload,
and to increased sympathetic activity, systemic vasoconstriction
and high left heart afterload. It may also be harmful because of
repetitive alkalosis during the waxing period of the cycle.
Finally, in some patients it is associated with repetitive arousal
from sleep, which causes severe sleep disruption, increased
sympathetic activity, and increased afterload.
[0010] Continuous positive airway pressure (CPAP) has been used for
decades for the emergency treatment of pulmonary oedema, and is
more recently being used longterm during sleep for the treatment of
cardiac failure. Nasal CPAP leads to an improvement in cardiac
output and ejection fraction, and an improvement in quality of life
[Naughton M T et al, Treatment of congestive heart failure and
Cheyne-Stokes respiration during sleep by continuous positive
airway pressure. Am J Respir Crit Care Med 1995; 151:92-97], and a
reduction in sympathetic nervous system activity [Naughton M T et
al, Effects of nasal CPAP on sympathetic activity in patients with
heart failure and central sleep apnea Am J Respir Grit Care Med
1995; 152:473-479]. The precise mechanism of action is unclear.
Making the alveolar pressure and right atrial pressure positive
with respect to the inferior vena caval pressure, and making the
left ventricular pressure more positive with respect to abdominal
aortic pressure, will tend to dry the lungs, improve gas exchange,
relieve paroxysmal nocturnal dyspnea, reduce reflex pulmonary
vasoconstriction, reduce sympathetic activity and reduce cardiac
afterload via multiple complex mechanisms. Standard nasal CPAP
masks may also help stabilize Cheyne-Stokes breathing, because the
effective ventilation cannot exceed the fresh gas flow, which is in
turn set by the exhaust flow. Finally, many patients with cardiac
failure also have coexisting obstructive sleep apnea, which worsens
cardiac failure but is treated by nasal CPAP.
[0011] Unfortunately, despite excellent effectiveness, nasal CPAP
is often poorly tolerated by patients with cardiac failure,
particularly early on in treatment, and it has not become widely
used. The reasons for the poor tolerance are unknown. In addition,
nasal CPAP reduces, but unfortunately does not immediately suppress
the Cheyne-Stokes breathing [Naughton M T et al. Effect of
continuous positive airway pressure on central sleep apnea and
nocturnal PCO2 in heart failure. Am J Respir Crit Care Med 1994;
150:1598-1604].
[0012] Various other approaches using known methods of ventilatory
assistance suggest themselves in order to provide the same benefit
as CPAP while also reducing either respiratory work or
Cheyne-Stokes breathing or both. Unfortunately no known device is
completely satisfactory, either because of discomfort,
overventilation, or both. For example, FIG. 1 shows persistent
Cheyne-Stokes breathing in a patient with cardiac failure being
treated with bilevel ventilatory support with timed backup. The
subject is in stage 3 non-REM sleep. The polygraph tracings are
arterial haemoglobin oxygen saturation (top tracing), chest wall
movement (middle tracing), and mask pressure (bottom tracing). The
Cheyne-Stokes breathing persists. Note, in the middle trace, the
cyclical waxing and waning of the amplitude of chest wall movement,
indicating periods of overbreathing and underbreathing, and
resultant regular decreases in arterial haemoglobin oxygen
saturation despite the ventilatory support.
[0013] Many classes of ventilator, far from increasing comfort,
actually decrease comfort. Volume cycled ventilators (regardless of
the trigger variable) and time triggered ventilators (regardless of
the cycling variable) often show very poor synchronization between
machine and patient, which is distressing to the patient. Volume
cycled ventilators and high impedance pressure cycled ventilators
do not permit the patient to increase or decrease ventilation
voluntarily, which is also distressing to the patient. Subjects
with Cheyne-Stokes breathing may be particularly distressed by
inadequate volume settings, due to their high chemoreceptor
gain.
[0014] Another serious problem is overventilation. Most ventilatory
assistance devices are designed to replace or augment respiratory
effort in subjects with respiratory failure or insufficiency, and
by design, cause a net increase in mean ventilation above the
subject's spontaneous mean ventilation. Unfortunately, in subjects
who are not initially acidotic, such as the subjects of the present
discussion, ventilatory assistance causes or exacerbates hypocapnia
and alkalosis, leading in turn to reflex upper airway and
particularly vocal cord closure during sleep [Jounieux et al.
Effects of nasal positive pressure hyperventilation on the glottis
in normal sleeping subjects. J Appl Physiol 1995; 79:186-193]. Far
from treating the disordered breathing, excessive ventilatory
support will actually produce closed airway central apneas. Some
ventilatory assistance devices, in an attempt to provide increased
comfort, support ventilation specifically during periods of
increased patient effort (for example proportional assist
ventilation and all classes of ventilators with spontaneous
triggering without timed backup). This will yet further enhance any
tendency to cyclically disordered breathing during sleep.
Similarly, in the case of volume cycled ventilators, awake comfort
can usually only be achieved by overventilation, with alkalosis and
consequent airway closure in sleep. Overventilation and alkalosis
can sometimes be extremely dangerous. Indeed, in patients with
cardiac failure and acute pulmonary edema, bilevel ventilation with
fixed high pressure swings appears to be associated with an
increased risk of myocardial infarction [Mehta et al. Randomized
prospective trial of brevet versus continuous positive airway
pressure in acute pulmonary oedema. Crit Care Med 1997;
25:620-628].
[0015] Another approach to the overventilation problem is to
provide ventilatory assistance only during periods of reduced
subject efforts, for example by triggering the ventilator only if
the subject has not produced an inspiration for at least a
specified period of time. This is unsatisfactory for three reasons.
Firstly, during spontaneous breathing, this solution will not
provide any increase in comfort over normal CPAP, and this was one
of the problems to be solved. Secondly, the sudden abrupt increase
in support at the onset of an apnea will in general tend to awaken
the patient from sleep, leading to both sleep fragmentation and
transient overventilation leading to further sleep disordered
breathing. Thirdly, as with all previous methods, it is difficult
to set the level of support during periods of central apnea high
enough to prevent Cheyne-Stokes breathing or central sleep apneas,
but not so high as to produce airway closure.
[0016] A more satisfactory approach is described in commonly owned
International Publication No. WO 98/12965, in which a target
ventilation is selected, and the degree of support is automatically
adjusted to servo-control the measured ventilation to at least
equal the target ventilation. A minimum level of support, chosen
not to produce overventilation, is provided for comfort during
awake breathing. If the target ventilation is chosen to be slightly
less than the eupneic ventilation, then Cheyne-Stokes breathing and
central sleep apnea may be prevented without the risk of
overventilation. Because the degree of support increases smoothly
as the subject's own efforts decrease, there is no explosively
sudden increase in support which might wake the patient. However,
there are two limitations to having a fixed target ventilation.
Firstly, the target ventilation needs to be chosen, and this can be
difficult: too high a value will lead to overventilation, while too
low a value will permit some residual Cheyne-Stokes breathing.
Secondly, due to changes in metabolic rate with restlessness, sleep
state, body temperature, meals, etc, the ideal target ventilation
is not constant.
[0017] In summary, longterm nasal CPAP therapy is of known benefit
in the treatment of cardiac failure, but is poorly tolerated, and
does not usually or completely alleviate Cheyne-Stokes breathing or
central sleep apnea, at least initially. Attempting to increase
tolerance and/or treat the disordered breathing using ventilatory
support is difficult, or only partially successful, depending on
the device used, because of the need to avoid overventilation. Very
similar comments apply to the treatment of Cheyne-Stokes breathing
and/or central sleep apnea due to many other causes in such as
stroke or acromegaly.
DISCLOSURE OF THE INVENTION
[0018] The present invention is directed to providing a subject
with cardiac failure positive airway pressure therapy, to achieve
an improvement in the symptoms and signs of cardiac failure similar
to that afforded by CPAP, by modulating the mask pressure in such a
way as to provide increased comfort without overventilation,
hypocapnia, alkalosis, or upper airway closure. The present
invention is further directed to the stabilization or prevention of
Cheyne-Stokes breathing or central sleep apnea from many
causes.
[0019] The invention discloses a method for treatment of cardiac
failure, Cheyne-Stokes breathing, or central sleep apnea,
comprising the steps of:
[0020] providing a subject with ventilatory support;
[0021] deriving a measure of instantaneous ventilation; and
[0022] adjusting the degree of ventilatory support to oppose short
term changes in said measure of instantaneous ventilation, but
permitting longterm changes in said measure of instantaneous
ventilation.
[0023] The invention further discloses apparatus for the treatment
of cardiac failure, Cheyne-Stokes breathing or central sleep apnea,
comprising:
[0024] a device for providing ventilatory support of controllable
magnitude;
[0025] means for deriving a signal indicative of instantaneous
ventilation of a subject;
[0026] a servo-controller operable to control the degree of
ventilatory support provided by said ventilatory support device to
oppose short-term changes in said measure of instantaneous
ventilation, but permit longterm changes in said measure of
instantaneous ventilation.
[0027] The invention discloses a method for treatment of cardiac
failure, Cheyne-Stokes breathing or central sleep apnea, comprising
the steps of:
[0028] providing a subject with ventilatory support;
[0029] deriving a measure of the subject's instantaneous
ventilation; and
[0030] adjusting the degree of ventilatory support to reduce
changes in said measure of instantaneous ventilation over a
timescale similar to that of the waxing-waning cycle of untreated
Cheyne-Stokes breathing or central sleep apnea, while allowing
changes in said measure of instantaneous ventilation over a
timescale much longer than said waxing-waning cycle.
[0031] The invention further discloses a method for treatment of
cardiac failure, Cheyne-Stokes breathing or central sleep apnea,
comprising the steps of:
[0032] providing a subject with ventilatory support;
[0033] deriving a measure of the subject's instantaneous
ventilation;
[0034] deriving a measure of the subject's longterm average
ventilation;
[0035] setting the controlled variable of a servo-controller to a
function of said measure of the subject's instantaneous
ventilation;
[0036] setting the reference variable of said servo-controller to a
measure of the subject's longterm average ventilation; and
[0037] adjusting the magnitude of said ventilatory support in
accordance with the output of said servo-controller.
[0038] The invention yet further discloses a method for treatment
of cardiac failure, Cheyne-Stokes breathing or central sleep apnea,
comprising the steps of:
[0039] providing a subject with ventilatory support;
[0040] deriving a measure of the subject's instantaneous
ventilation;
[0041] high pass filtering said measure of the subject's
instantaneous ventilation; and
[0042] adjusting the degree of said ventilatory support inversely
with said high pass filtered measure of the subject's instantaneous
ventilation.
[0043] The invention also discloses a method for the treatment of
cardiac failure, Cheyne-Stokes breathing or central sleep apnea,
comprising the steps of:
[0044] providing a subject with positive pressure ventilatory
support, with controllable amplitude and rate;
[0045] deriving a measure of the subject's instantaneous
ventilation;
[0046] adjusting said amplitude of positive pressure by: [0047] (a)
low pass filtering said measure of instantaneous ventilation to
derive a measure of recent average ventilation; [0048] (b) setting
a target ventilation equal to a fraction of said measure of recent
average ventilation; and [0049] (c) servo-controlling said measure
of instantaneous ventilation to at least equal the target
ventilation, by adjusting the degree of ventilatory support;
[0050] continuously adjusting said rate by: [0051] (a) to the
extent that the instantaneous ventilation equals or exceeds said
target ventilation, modulating said positive pressure in phase with
respiratory airflow; and [0052] (b) to the extent that the
instantaneous ventilation is less than said target ventilation,
modulating said positive pressure at a pre-set rate.
[0053] The invention further discloses apparatus for treatment of
cardiac failure, Cheyne-Stokes breathing or central sleep apnea,
comprising:
[0054] a controllable source of breathable gas at positive
pressure;
[0055] means for delivering said breathable gas at positive
pressure to a subject's airway;
[0056] means for deriving a measure of the subject's instantaneous
ventilation; and servo-controller for adjusting the degree of
ventilatory support to reduce changes in said measure of
instantaneous ventilation over a timescale similar to that of the
waxing-waning cycle of untreated Cheyne-Stokes breathing or central
sleep apnea, while allowing changes in said measure of
instantaneous ventilation over a timescale much longer than said
waxing-waning cycle.
[0057] The invention yet further discloses apparatus for treatment
of cardiac failure, Cheyne-Stokes breathing or central sleep apnea,
comprising:
[0058] a controllable source of breathable gas at positive
pressure;
[0059] means for delivering said breathable gas at positive
pressure to a subject's airway;
[0060] means for deriving a measure of the subject's instantaneous
ventilation;
[0061] means for deriving a measure of the subject's longterm
average ventilation;
[0062] means for deriving a target ventilation as a function of
said measure of the subject's longterm average ventilation;
[0063] a servo-controller, whose input variable is a function of
said measure of the subject's instantaneous ventilation, and whose
reference variable is said target ventilation; and
[0064] means for adjusting the magnitude of said ventilatory
support according to the output of the servo-controller.
[0065] The invention also discloses apparatus for the treatment of
cardiac failure, Cheyne-Stokes breathing or central sleep apnea,
comprising:
[0066] ventilator means for providing ventilatory support with
controllable amplitude and rate;
[0067] sensor and processing means for deriving a signal indicative
of instantaneous ventilation of a subject; and
[0068] servo-control means operable to adjust the amplitude of the
pressure support by low pass filtering said instantaneous
ventilation signal to derive a measure of recent average
ventilation, setting a target ventilation equal to a fraction of
said measure of recent average ventilation, and servo-controlling
said measure of instantaneous ventilation to at least equal the
target ventilation, and further operable to continuously adjust
said rate by modulating said positive pressure in phase with
respiratory airflow to the extent that the instantaneous
ventilation equals or exceeds said target ventilation, and
modulating said positive pressure at a pre-set rate to the extent
that the instantaneous ventilation is less than said target
ventilation.
[0069] Embodiments of the invention provide a degree of ventilatory
support which many subjects will perceive as very comfortable.
Cheyne-Stokes breathing is reduced or eliminated. Unlike the case
of prior art taught in International Publication No. WO98/12965,
the physician is not required to estimate or empirically determine
a target ventilation, as this is done automatically. The risk of
overventilating the subject and causing alkalosis or airway closure
is also reduced.
BRIEF DESCRIPTION OF THE DRAWINGS
[0070] Embodiments of the present invention will now be described,
by way of example only, with reference to the accompanying
drawings.
[0071] FIG. 1 is a plot of a 10 minute excerpt from a polygraph
tracing from a sleeping patient with cardiac failure, during
treatment with prior art bilevel ventilation in Stage Ill non-REM
sleep.
[0072] FIG. 2 is a schematic diagram of ventilation apparatus
embodying the invention.
[0073] FIG. 3 is a plot of a pressure waveform template. The
horizontal axis .phi. is the phase in the respiratory cycle,
measured in revolutions, such that 0 is start of inspiration, 0.5
revolutions is start of expiration, and 1 revolution is end of
expiration.
[0074] FIG. 4 is a plot of a 10 minute excerpt from a polygraph
tracing from the subject from FIG. 1, also in Stage III non-REM
sleep, being treated by an embodiment of the present invention.
Cheyne-Stokes breathing has been eliminated.
[0075] FIG. 5 is a schematic diagram showing respiratory airflow
during Cheyne-Stokes breathing, and various calculated quantities,
including two measures of "instantaneous" ventilation, "recent
average" ventilation, and "target" ventilation with time.
[0076] FIG. 6 is a schematic diagram showing, for a preferred
embodiment, the expected increase in degree of ventilatory support
in response to a sudden cessation of all respiratory efforts by the
subject with time.
[0077] FIG. 7 is a schematic diagram showing, for the preferred
embodiment, how the degree of assistance will remain at the minimum
level if the subject's ventilation steadily decreases over a very
long time period.
DETAILED DESCRIPTION
[0078] A ventilator embodying one form of the invention is shown in
FIG. 2 in which a blower 10 supplies breathable gas to a mask 11
for communication with a subject's airway via a delivery tube 12
and exhausting to atmosphere via an exhaust 13. Airflow at the mask
11 is measured using a pneumotachograph 14 and a differential
pressure transducer 15. The mask flow signal 22 from the transducer
15 is sampled by a microcontroller 16. Mask pressure is measured at
port 17 using a pressure transducer 18. The pressure signal 24 from
the transducer 18 is also sampled by the microcontroller 16. The
microcontroller 16 sends an instantaneous mask pressure request
signal 26 to a servo 19, which compares the pressure request signal
(ie. the desired pressure signal) 26 with the actual pressure
signal 24 from the transducer 18 to control a motor 20 driving the
blower 10. The microcontroller 16 settings can be adjusted via a
serial port 21.
[0079] It is to be understood that the mask could equally be
replaced with a tracheotomy tube, endotracheal tube, nasal pillows,
or other means of making a sealed connection between the air
delivery means and the subject's airway.
[0080] The steps performed by the microcontroller 16 to determine
the requested mask pressure will now be described.
[0081] The microcontroller 16 accepts the mask airflow and pressure
signals 22, 24, and from said signals determines the instantaneous
flow through any leak between the mask and subject, by any
convenient method. For example, the conductance of the leak may be
estimated as the instantaneous mask airflow low pass filtered with
a time constant of 10 seconds, divided by the similarly low pass
filtered square root of the instantaneous mask pressure, and the
instantaneous leakage flow may be calculated as said conductance
multiplied by the square root of the instantaneous mask pressure.
Respiratory airflow is then calculated as the instantaneous mask
airflow minus said instantaneous leakage flow.
[0082] Having determined the respiratory airflow, the
microcontroller 16 now determines the subject's recent average
absolute respiratory airflow as the 100 second low pass filtered
absolute value of the respiratory airflow. The 100 second time
constant is chosen because it is long compared with the
lung-chemoreceptor delay in patients with Cheyne-Stokes breathing
or central sleep apnea (typically up to 20 sec), and somewhat
longer than the cycle time of typical Cheyne-Stokes breathing of
about 60 seconds. Longer time constants will in principle give
better suppression of Cheyne-Stokes breathing as long as the
subject's chemoreceptor set-point is constant, but will take longer
to settle at sleep onset and longer to track changes in set-point.
The term "recent average" is used in the sense of recent compared
with an entire night's sleep. However, compared with
"instantaneous" ventilation, which is measured on a timescale of a
single breath or less, the 100 second low pass filtered absolute
value of the respiratory airflow is, of course, a longterm
average.
[0083] A target absolute respiratory airflow is then calculated as
95% of said recent average absolute respiratory airflow. Larger
values can result in positive feedback leading to drift in the
ventilation, while smaller values will permit residual
Cheyne-Stokes breathing.
[0084] FIG. 5 shows the above steps schematically. The top tracing
in the figure is respiratory airflow. The second tracing, labelled
"Instantaneous Ventilation 1", is the absolute value of the
respiratory airflow. The bottom tracing shows, schematically,
another measure of instantaneous ventilation, labelled
"Instantaneous Ventilation 2", which is Instantaneous Ventilation 1
low pass filtered with a time constant of a few breaths.
Instantaneous Ventilation 2, as a measure of ventilation, could
equally be schematically the recent average ventilation and the
target ventilation.
[0085] Having calculated the target ventilation, a microcontroller
now calculates a mask pressure modulation amplitude A. The object
of this step is to modulate the pressure modulation amplitude in a
direction opposite to changes in the output from the subject's own
respiratory controller, providing more support when the subject is
making shallow efforts, and less support when the subject is making
strong efforts, thus stabilizing the subject's breathing. It is
necessary in this step that the servo-controller should have a
delay that is very short compared with the delay in the subject's
own respiratory controller; a long delay would further destabilize
the subject's breathing. If a proportional or integral controller
were fed with a measure of the subject's ventilation taken over
many seconds, for example, longer than the case of "Instantaneous
Ventilation 2" in FIG. 5, the controller delay would be too long.
Conversely, if a proportional controller were supplied with the
rectified instantaneous respiratory airflow (as in Instantaneous
Ventilation 1 in FIG. 5), then the controller output would be
varying out of phase with the subject's breathing efforts, and the
subject would perceive an increase in the work of breathing. In the
present implementation, a clipped integral controller is fed with
Instantaneous Ventilation 1, the absolute value of the respiratory
airflow. The process of integration both smooths and delays
within-breath changes in the amplitude A, so that the subject does
not perceive any increase in work of breathing. A suitable
algorithm is as follows: [0086] calculate an error term e equal to
the instantaneous absolute respiratory airflow minus the target
absolute respiratory airflow; [0087] set the pressure modulation
amplitude A equal to
[0087] A=fGedt [0088] where G is the controller integral gain,
typically -0.3 cmH.sub.20 L/min per second, and the integral A is
clipped to a convenient range such as 3-12 cmH.sub.20.
[0089] Larger values of G can result in positive feedback in the
controller. Smaller values will permit some residual untreated
Cheyne-Stokes breathing or central sleep apnea. The minimum
amplitude (3 cmH20 being a suitable value suitable for most
subjects) is chosen to be of the order of 50% of the estimated
amplitude required to perform all the respiratory work of the
subject in the steady state. A minimum value of this order of
magnitude provides much improvement in comfort over a minimum value
of zero. The maximum amplitude (12 cmH20 being typical) is chosen
to be approximately double the amplitude that would perform all the
respiratory work of the subject (and therefore sufficient to
support the subject's breathing if they cease making any efforts)
but less than a value that would be uncomfortable or dangerous.
[0090] The microcontroller 16 then determines the instantaneous
phase .phi. in the respiratory cycle from the instantaneous
respiratory airflow, looks up a pressure waveform template
II(.phi.) and sets the instantaneous mask pressure to:
P.sub.mask=P.sub.0+AII(.phi.)
[0091] where P.sub.o is an end expiratory pressure, typically 5-10
cmH.sub.2O, but chosen to be sufficient to treat any underlying
obstructive sleep apnea syndrome.
[0092] In a simplest embodiment, the respiratory phase is taken as
bivalued: inspiratory if the instantaneous respiratory airflow is
positive, and expiratory otherwise, and II(.phi.) is unity for
inspiration and zero for expiration. If phase has been expiratory
for more than a set time, chosen to be slightly longer than the
subject's normal expiratory time, then the phase is switched to
inspiratory.
[0093] In another embodiment, .phi. is a continuous variable from
zero to 1 revolution, and the pressure waveform template II(.phi.)
is as shown in FIG. 3. In this embodiment, the microcontroller
determines .phi. using the following fuzzy logic rules:
[0094] 1. If the airflow is zero and increasing fast then the phase
is 0 revolutions.
[0095] 2. If the airflow is large positive and steady then the
phase is 0.25 revolutions.
[0096] 3. If the airflow is zero and falling fast then the phase is
0.5 revolutions.
[0097] 4. If the airflow is large negative and steady then the
phase is 0.75 revolutions.
[0098] 5. If the airflow is zero and steady and the 5 second low
pass filtered absolute value of the respiratory airflow is large
then the phase is 0.9 revolutions.
[0099] 6. If the airflow is positive and the phase is expiratory,
then the phase is 0 revolutions.
[0100] 7. If the airflow is negative and the phase is inspiratory,
then the phase is 0.5 revolutions.
[0101] 8. If the 5 second low pass filtered absolute value of the
respiratory airflow is small, the phase in the respiratory cycle is
increasing at a fixed rate equal to the subject's expected
respiratory rate.
[0102] 9. If the 5 second low pass filtered absolute value of the
respiratory airflow is large, the phase in the respiratory cycle is
increasing at a steady rate equal to the existing rate of change of
phase, low pass filtered with a time constant of 20 seconds.
[0103] The fuzzy extent to which the airflow is "large", "steady",
etc can be determined with suitable membership functions.
[0104] Rules 1-4 estimate the phase directly from the instantaneous
respiratory airflow. Rule 5 permits an expiratory pause, whose
length may be long if the subject has recently been breathing
adequately, and short or zero if the subject is not breathing. This
is particularly appropriate for subjects with Cheyne-Stokes
breathing, because an expiratory pause should not be permitted if
the subject is apneic. Rules 6-7 provide for quick
resynchronization in the event that the subject breathes
irregularly. Rule 8 provides the equivalent of a timed backup, in
which, to the extent that the subject has stopped breathing or is
not adequately breathing, the ventilator will cycle at a suitable
fixed rate. Rule 9 provides that to the extent that the subject is
breathing adequately, the ventilator will tend to track the
subject's recent average respiratory rate. This is particularly
appropriate in subjects with cardiac failure and Cheyne-Stokes
breathing, whose respiratory rate tends to be extremely steady
despite rhythmic changes in amplitude.
[0105] An effect of the changing degree of activation of rules 8
and 9 is that, to the fuzzy extent that the instantaneous
ventilation equals or exceeds the target ventilation, ventilatory
support will be provided in phase with the subject's own
respiratory efforts, and to the extent that the instantaneous
ventilation is less than the target ventilation, ventilatory
support will be provided at a pre-set rate.
[0106] In an elaboration of this embodiment, the weighting of rules
1-6 can be made proportional to the fuzzy extent that the
instantaneous ventilation is large compared with the target
ventilation. This strengthens the tendency for the device to act as
described in the previous paragraph.
[0107] In a further elaboration, the weighting of rules 1-6 and
also of rule 9 can be made smaller, and the weighting of rule 8 can
be larger, if the leak is large, or if there is a sudden change in
the leak. In this way, to the extent that the respiratory airflow
signal is of high quality, ventilatory support will be provided as
described in the preceding paragraphs, but to the extent that the
respiratory airflow signal is of poor quality and it is difficult
to synchronize reliably with the patient's efforts, or to know if
the patient's efforts are adequate, ventilatory support will be
provided in an orderly manner at a predetermined fixed rate.
[0108] Assuming that the sleeping subject's PC02 is stable at
slightly above the subject's chemoreceptor set-point and the airway
is open, the system will remain stable. This is explained as
follows. The minimum amplitude, A, of 3 cmH20 will be unloading
some of the subject's high work of breathing, but is too small to
provide all the respiratory work needed to maintain ventilation and
PC02 at the subject's set-point. Therefore, there will be an error
signal from the subject's chemoreceptors. Therefore the subject
will be making spontaneous ventilatory efforts (but less than
usual), and the upper airway will be patent. Since the target
ventilation is only 95% of the spontaneous ventilation, the actual
ventilation will be slightly higher than the target ventilation,
and the integrator determining amplitude A will remain clipped at
the minimum amplitude. If there is a primary reduction in the
subject's ventilation of more than 5% due to a primary reduction in
ventilatory effort or increase in airway resistance, there will be
an immediate and rapid increase in the amplitude A by sufficient to
maintain ventilation at a level of at least 95% of the previous
spontaneous level, thus preventing hypopneas.
[0109] An example is shown schematically in FIG. 6. For the first 4
breaths, the subject is making steady respiratory efforts, and the
pressure modulation amplitude A remains at the minimum value of 3
cmH.sub.20. Respiratory airflow is due to the combined efforts of
subject and ventilation apparatus. At the first vertical line, I,
the subject's spontaneous efforts cease. For the next 12 breaths,
all respiratory airflow is due only to the machine. The first
breath is delivered approximately on schedule, but produces less
respiratory airflow than usual, because only the minimum degree of
support is provided. Over the next few breaths, the amplitude A
quickly increases to the maximum of 10 cmH.sub.20, restoring
respiratory airflow to almost its original level. At the second
vertical line, II, the subject recommences spontaneous respiratory
efforts at the previous level, and the degree of machine generated
support quickly reduces again. It is to be noted in FIG. 6 that
during a period of cessation of spontaneous effort, the subject
will be ventilated at the preset respiratory rate, due to the
operation of fuzzy rule 8. Conversely, during the periods of normal
effort, support is provided in phase with the subject's efforts.
These may be slower than the preset rate (as in FIG. 6) or they may
be faster than the preset rate.
[0110] The subject can acutely increase their spontaneous
ventilation at will. Transient increases in ventilation for example
due to brief arousals will lead to a small degree of hypocapnia,
but the resultant secondary reduction or cessation in subject's
efforts will again be immediately matched by an increase in
amplitude A sufficient to hold ventilation at a level of at least
95% of the previous steady level. Conversely, gradual changes in
the subject's chemoreceptor set-point over minutes will result in
gradual changes in target ventilation, which will remain at 95% of
the subject's actual ventilation. This is shown schematically in
FIG. 7. The lower tracing shows respiratory airflow gradually
decreasing over a 30 minute period. The calculated recent average
ventilation and target ventilation (middle trace) similarly decline
over the thirty minutes. However, since the recent average
ventilation is always larger than the target ventilation, the
degree of support always remains at the minimum (top tracing).
[0111] An embodiment of the invention was tested in ten patients
with severe cardiac failure and Cheyne-Stokes breathing during
sleep. The target ventilation was initially set to 5-7.5 L/min, and
the end expiratory pressure P.sub.0 was set to 8 cmH.sub.20. The
patients were tested on each one of a control night (no
assistance), nasal oxygen at 2 L/min, CPAP (7-10 cmH.sub.2O as
tolerated, bi-level CPAP (ResMed VPAP-ST.TM. machine, with VPAP at
4 cmH.sub.20 and IPAP at 12-18 cmH.sub.20 as required, with the
backup rate at 2 L/min below the spontaneous rate), and a prototype
of the present applicant's Auto CS.TM. machine.
[0112] The apnea+hypopnea index (AHI), ASDA microarousal index
(ARI), and percentage of time in slow wave (SWS) and REM sleep were
calculated using standard procedures. The results are presented as
mean.+-.sem. The statistical analysis is repeated measures ANOVA
after rank transform.
TABLE-US-00001 Control Oxygen CPAP VPAP-ST Auto CS AHI (hr.sup.-1)
43.3 .+-. 5.sup.+ 48.8 .+-. 3.2.sup.+ 24.1 .+-. 3.4.sup.+ 9.0 .+-.
1.3.sup.+ 4.8 .+-. 0.9.sup.+ ARI (hr.sup.-1) 48.1 .+-. 3.6.sup.+
34.7 .+-. 4.5.sup.+ 30.8 .+-. 3.5.sup.+ 18.4 .+-. 3.4.sup. 15.5
.+-. 3.2.sup.+ SWS (%) 13.7 .+-. 2.8.sup.+ 19.8 .+-. 2.6.sup.+ 19.3
.+-. 3.5.sup.+ 20.8 .+-. 3.05.sup.+ 21.1 .+-. 2.7.sup.+ REM (%)
10.5 .+-. 2.1.sup.+ 13.3 .+-. 2.4.sup.+ 12.2 .+-. 1.6.sup.+ 15.3
.+-. 2.3.sup.+ 18.4 .+-. 0.6.sup.+ *Auto CS P < 0.05, .sup.+Auto
CS P < 001.
[0113] In most subjects, transcutaneous PCO.sub.2 fell by
approximately 5-10 mmHg due to a period of hyperventilation in the
first few minutes of awake breathing. This resulted in some
instability of the upper airway and residual mild Cheyne-Stokes
breathing for the first 20-40 minutes of sleep. Subsequently,
Cheyne-Stokes breathing was largely abolished. FIG. 4 shows the
same subject as FIG. 1, also in stage 3 non-REM sleep, but this
time using the new device. The mask pressure swings are broadly
comparable with those in FIG. 1, but very small changes with time
can be seen, as the device opposes any changes in the subject's
ventilation. It is clear that the subject's ribcage movement (ie.
measured using a thoracic respiratory band) and oxygen saturation
(Sa02) are greatly stabilized compared with FIG. 1, and
Cheyne-Stokes breathing has been eliminated.
[0114] In some subjects, the period of unstable breathing
immediately after sleep onset could be eliminated by asking the
subject to remain awake for 20 minutes after applying the mask and
before going to sleep, in order to minimize overbreathing
immediately prior to sleep onset.
* * * * *